According to researchers in the UK, an experimental cancer therapy has completely eliminated prostate cancer in experiments on mice.
The "Trojan-horse" therapy is so called because it works by hiding cancer-killing viruses inside the immune system. The viruses are then able to sneak into the tumour, and once inside, tens of thousands of viruses are released to kill the cancerous cells.
Using viruses to destroy rapidly growing rumours is an emerging field in cancer therapy, but one of the challenges is getting the viruses deep inside the tumour where they can do the damage. The team involved in the experiment, led by Prof. Claire Lewis from the University of Sheffield, used white blood cells to deliver the virus into the cells.
After chemotherapy or radiotherapy is used to treat cancer, there is damage to the tissue. This causes a surge in white blood cells, which swamp the area to repair the damage; the therapy makes use of this by "piggy-backing" the virus onto the white blood cells.
In the experiment the team took blood samples from the mice before extracting macrophages and mixing them with a virus. The mice were then given a course of chemotherapy and two days after they were injected with the white blood cells. At the time of injection each cell contained just a couple of viruses, but 12 hours later the macrophages burst and eject up to 10,000 viruses each; these then go on to infect and kill the cancerous cells.
At the end of the 40-day study, all the mice who received the treatment were still alive and showed no signs of tumours. Prof. Lewis now hopes to begin human trials next year and says: "If this treatment goes on to be successful in human trials, it could mark substantial progress in finding better treatments for men with prostate cancer which has spread to the bone." There is however need for caution as many remarkable advances in treating mice have failed to have any effect in people.
Jack
Friday, 28 December 2012
Friday, 21 December 2012
Alzheimer's disease treated by blocking immune response
Researchers from the German Center for Neurodegenerative Diseases, DZNE, as well as the University of Bonn, have discovered that the protein complex NLRP3 is a critical factor in the development of Alzheimer's disease.
The researchers studied the complex "NLRP3 inflammasome" which is already known to have a very important role in the immune system. Its activation means that immune cells are mobilised and inflammation-causing substances can be released.
Alzheimer's disease occurs when plaques begin forming in the brain, which then activate the NLRP3 inflammasome. The researchers in this study looked at the effects that its increased activity has on the brain.
Prof. Michael Heneka and his team studied the brains of dead Alzheimer's patients and mice with disorders that are related to Alzheimer's disease. It was found that the NLRP3 was active in both the humans and the mice. The researchers believed that by suppressing the inflammatory reactions of the protein complex there would be a reduction in the damaging plaques. They then removed the genes that activates NLRP3 inflammasome activity in another group of mice, which meant they were no longer able to synthesise the protein complex. The result of this was that they only showed mild symptoms of Alzheimer's-associated disorders.
This research could result in pharmaceuticals being developed to target the protein complex and inhibit its activity, and the team are already looking for potential ways to block the inflammasome. Prof. Heneka commented: "The testing of potential substances in the laboratory would be a next step. We hope to start as early as next year."
Jack
The researchers studied the complex "NLRP3 inflammasome" which is already known to have a very important role in the immune system. Its activation means that immune cells are mobilised and inflammation-causing substances can be released.
Alzheimer's disease occurs when plaques begin forming in the brain, which then activate the NLRP3 inflammasome. The researchers in this study looked at the effects that its increased activity has on the brain.
Prof. Michael Heneka and his team studied the brains of dead Alzheimer's patients and mice with disorders that are related to Alzheimer's disease. It was found that the NLRP3 was active in both the humans and the mice. The researchers believed that by suppressing the inflammatory reactions of the protein complex there would be a reduction in the damaging plaques. They then removed the genes that activates NLRP3 inflammasome activity in another group of mice, which meant they were no longer able to synthesise the protein complex. The result of this was that they only showed mild symptoms of Alzheimer's-associated disorders.
This research could result in pharmaceuticals being developed to target the protein complex and inhibit its activity, and the team are already looking for potential ways to block the inflammasome. Prof. Heneka commented: "The testing of potential substances in the laboratory would be a next step. We hope to start as early as next year."
Jack
Friday, 14 December 2012
Child's leukaemia cured by re-engineered immune cells
A seven-year-old girl in the US with an aggressive form of childhood leukaemia has been cured using her own re-engineered immune cells, thanks to an experimental new therapy. Once the treatment had been carried out, the girls's doctors could find no evidence of any remaining cancer.
The girl, Emily, was the first child patient on a clinical trial that is testing T cell therapy to treat acute lymphoblastic leukaemia, as well as other B cell cancers. B cells are the type of White blood cell that becomes cancerous in some leukaemias and lymphomas.
In the trial, known as CTL019, Emily received a custom-designed version of her own T cells, which then rapidly multiplied and destroyed the leukaemia cells. The T cells, which do the job of recognising and attacking invading pathogens, were taken from the girl before being genetically modified by the researchers. They were modified to express a protein that binds to a target called CD19, a protein found on the surface of all B cells, including the cancerous ones. Normally, B cells are capable of remaining undetected by T cells, but the genetic modification makes them able to detect and destroy the cancerous B cells.
The modified T cells were then put back into the patient where they disperse and go in search of cancerous B cells. They also multiply at a rate that allows them to stay on top of the rapidly-dividing cancer cells, and stay in the body to continue fighting any new cancerous cells.
The team hopes that CTL019 will prove an effective therapy for patients with B cell cancers, but because only 12 patients took part in the trial, more adult and paediatric patients need to be enrolled to see if the same results are seen in a larger group.
Jack
The girl, Emily, was the first child patient on a clinical trial that is testing T cell therapy to treat acute lymphoblastic leukaemia, as well as other B cell cancers. B cells are the type of White blood cell that becomes cancerous in some leukaemias and lymphomas.
In the trial, known as CTL019, Emily received a custom-designed version of her own T cells, which then rapidly multiplied and destroyed the leukaemia cells. The T cells, which do the job of recognising and attacking invading pathogens, were taken from the girl before being genetically modified by the researchers. They were modified to express a protein that binds to a target called CD19, a protein found on the surface of all B cells, including the cancerous ones. Normally, B cells are capable of remaining undetected by T cells, but the genetic modification makes them able to detect and destroy the cancerous B cells.
The modified T cells were then put back into the patient where they disperse and go in search of cancerous B cells. They also multiply at a rate that allows them to stay on top of the rapidly-dividing cancer cells, and stay in the body to continue fighting any new cancerous cells.
The team hopes that CTL019 will prove an effective therapy for patients with B cell cancers, but because only 12 patients took part in the trial, more adult and paediatric patients need to be enrolled to see if the same results are seen in a larger group.
Jack
Saturday, 8 December 2012
Increase in cancer survival
According to figures from the Office for National Statistics, fewer people in the UK are dying from cancer, despite an increase in the number of people being diagnosed. An analysis of data from 2008-10 shows that there are nearly 323,000 cancer diagnoses each year, and 156,200 patients died in each of those years.
The data also showed that for 2001-03 there were 403 new cancer cases for every 100,000 men and 343 for every 100,000 women. The 2008-10 analysis then showed that these figures increased to 431 per 100,000 men and 375 per 100,000 women.
In addition it was shown that, between 2001-03 and 2008-10, the number of deaths decreased from 229 to 204 per 100,000 men, and 161 to 149 per 100,000 women.
The head of statistical information at Cancer Research UK, Catherine Thomson, said: "While overall cancer incidence rates have continued to rise, death rates have fallen - by 11% for men and 7.5% for women since the start of the century."
This means that each individual's risk of dying from the disease has fallen, which has been helped hugely by the reduction in people smoking, as well as an improvement in the ability to diagnose it. Another factor is the progress that has been made in chemotherapy, radiotherapy and surgery, and the development of personalised medicine.
Jack
The data also showed that for 2001-03 there were 403 new cancer cases for every 100,000 men and 343 for every 100,000 women. The 2008-10 analysis then showed that these figures increased to 431 per 100,000 men and 375 per 100,000 women.
In addition it was shown that, between 2001-03 and 2008-10, the number of deaths decreased from 229 to 204 per 100,000 men, and 161 to 149 per 100,000 women.
The head of statistical information at Cancer Research UK, Catherine Thomson, said: "While overall cancer incidence rates have continued to rise, death rates have fallen - by 11% for men and 7.5% for women since the start of the century."
This means that each individual's risk of dying from the disease has fallen, which has been helped hugely by the reduction in people smoking, as well as an improvement in the ability to diagnose it. Another factor is the progress that has been made in chemotherapy, radiotherapy and surgery, and the development of personalised medicine.
Jack
Subscribe to:
Posts (Atom)

